What is MapLight Therapeutics, Inc. 's debt issuance costs?

MapLight Therapeutics, Inc. (MPLT) reported debt issuance costs of $3.89M in Q4 2025.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

MapLight Therapeutics, Inc. MPLT Debt Issuance Costs

Debt Issuance Costs at other companies

Taysha Gene Therapies, Inc.TSHA

$18K-82.0%

Rapport Therapeutics, Inc.RAPP

$273K—

Maze Therapeutics, Inc. Common StockMAZE

$886K—

Amneal Pharmaceuticals, Inc.AMRX

$1.98M—

AlkermesALKS

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: MapLight Therapeutics, Inc. ’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's debt issuance costs?: MapLight Therapeutics, Inc. (MPLT) reported debt issuance costs of $3.89M in Q4 2025.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.